A Study on the Possible Health Effects of Lean Fish, Fatty Fish and Lean Meat Intake in Non-obese Adults

Obesity Clinical Trial

— FISK1  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02130908
• Other study ID #: REK2011/572
• Status: Completed
• Phase: N/A
• Start date: March 2011
• Est. completion date: July 2015

Study information

• Verified date: May 2018
• Source: University of Bergen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a pilot study to investigate whether intake of lean or fatty fish, or lean meat would affect parameters related to health in healthy non-obese adults, and will serve as basis for future calculation of group sizes in coming studies. Participants consumed 750g/week of fillets of fish or meat for 4 weeks.

Hypothesis:

High intake of either lean or fatty fish will not affect serum concentrations of lipids and inflammatory markers as well as improve glucose tolerance during the 4 week intervention period when compared to lean meat intake.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 35 Years

Eligibility

Inclusion Criteria:

• adults

• non-obese

• healthy

Exclusion Criteria:

• diabetes

• diagnosed diseases of the intestine or cardiovacular system

Related Conditions & MeSH terms

• Metabolic Diseases
• Metabolic Disorders
• Obesity

Intervention

Other:
• Lean fish
Participants consumed 150g of lean fish, five times per week for 4 weeks
• Fatty fish
Participants consumed 150g of fatty fish, five times per week for 4 weeks
• Lean meat
Participants consumed 150g of lean meat, five times per week for 4 weeks

Locations

Country	Name	City	State
Norway	Haukeland University Hospital	Bergen

Sponsors (4)

Lead Sponsor	Collaborator
University of Bergen	Bergen Medical Research Foundation, Leroy Seafood Group ASA, Skretting ASA

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in metabolic parameters (lipids, glucose, inflammatory markers) measured in serum		Endpoint after 4 weeks intervention
Secondary	Changes in body weight		Endpoint after 4 weeks intervention